Core Viewpoint - Chengda Pharmaceutical (301201.SZ) is currently experiencing a decline in stock price, closing at 40.70 yuan with a drop of 3.85%, indicating it is in a state of breaking below its initial public offering price [1] Group 1: IPO and Financials - Chengda Pharmaceutical was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on January 20, 2022, with an initial public offering of 24,174,035 shares at a price of 72.69 yuan per share [1] - The highest price recorded on the first day of trading was 188.00 yuan, marking the peak since its listing [1] - The total funds raised from the IPO amounted to 1,757.21 million yuan, with a net amount of 1,621.45 million yuan after deducting issuance costs [1] - The actual net fundraising exceeded the original target by 1,108.17 million yuan, with the initial target set at 513.28 million yuan for projects including pharmaceutical intermediates, raw materials, and R&D center expansion [1] Group 2: Shareholder Returns - On July 3, 2023, Chengda Pharmaceutical announced its 2022 annual equity distribution plan, which includes a cash dividend of 3.00 yuan for every 10 shares and a capital reserve increase of 6.00 shares for every 10 shares held [2] - The record date for this equity distribution was set for July 6, 2023, with the ex-dividend date on July 7, 2023 [2] Group 3: Management - The actual controllers of Chengda Pharmaceutical are Ge Jianli, Lu Gang, and Lu Jin, with Lu Jin holding Canadian permanent residency [2]

证券之星消息，12月31日化学制药板块较上一交易日下跌0.31%，信立泰领跌。当日上证指数报收于 3968.84，上涨0.09%。深证成指报收于13525.02，下跌0.58%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300573 | 兴齐眼药 | 7439.59万 | 13.65% | -697.93万 | -1.28% | -6741.66万 | -12.37% | | 000963 | 华东医药 | 6823.36万 | 18.91% | -4988.17万 | -13.83% | -1835.19万 | -5.09% | | 300086 | 康芝药业 | 3651.55万 | 3.67% | 4453.79万 | 4.47% | -8105.34万 | -8.14% | | 301246 | 宏源药业 | 3493.05万 | 3.27% | -208.79万 | - ...

中欧医疗健康混合A（003095）基金经理为葛兰、赵磊。 12月31日，海思科涨1.03%，截至发稿，报51.14元/股，成交4214.92万元，换手率0.17%，总市值572.73 亿元。 资料显示，海思科医药集团股份有限公司位于西藏山南市泽当镇三湘大道17号，成立日期2005年8月26 日，上市日期2012年1月17日，公司主营业务涉及化学药品的研究开发、生产制造、销售推广。主营业 务收入构成为：麻醉产品39.81%，合作产品相关收入23.59%，其他适应症17.02%，肠外营养系 10.32%，肿瘤止吐8.15%，其他(补充)0.86%，其他主营业务收入0.26%。 从海思科十大流通股东角度 数据显示，中欧基金旗下1只基金位居海思科十大流通股东。中欧医疗健康混合A（003095）三季度增 持12.12万股，持有股数2139.75万股，占流通股的比例为4.44%。根据测算，今日浮盈赚取约1112.67万 元。 中欧医疗健康混合A（003095）成立日期2016年9月29日，最新规模169.77亿。今年以来收益13.6%，同 类排名5297/8085；近一年收益11.58%，同类排名5431/8085；成立 ...

截至2025年12月30日收盘，博瑞医药(688166)报收于49.4元，下跌0.66%，换手率0.98%，成交量4.14万 手，成交额2.05亿元。 当日关注点 交易信息汇总 第四届董事会第十六次会议决议公告 博瑞医药第四届董事会第十六次会议于2025年12月29日召开，审议通过《关于募集资金投资项目延期的 议案》，将多个募投项目达到预定可使用状态时间延期至2027年3月。同时审议通过修订及制定公司部 分内部治理制度的议案，涉及累积投票制、独立董事制度、董事会各专门委员会工作制度、募集资金使 用管理、对外担保、对外投资、内幕信息管理等多项制度。所有议案均获全票通过。 内部审计管理制度（2025年12月） 博瑞生物医药（苏州）股份有限公司制定内部审计制度，明确内部审计机构在审计委员会领导下独立开 展工作，负责对公司及下属单位的内部控制、财务信息、经营活动等进行审计监督。制度规定了内部审 计的职责、权限、工作程序及审计范围，包括内部控制审计、运营审计、合规审计、舞弊审计、经济责 任审计、专项审计和信息系统审计等。内部审计机构需定期向审计委员会报告，并对发现问题的整改情 况进行跟踪。公司对审计人员履职予以保障，严 ...

（文章来源：证券日报） 证券日报网讯 12月30日，浙江震元在互动平台回答投资者提问时表示，公司组氨酸自投产以来，结合 市场需求安排生产计划，产销情况良好。 ...

在相继披露了法院裁定不予受理重整申请暨子公司宣告破产、公司股票可能被实施重大违法强制退市相关风险、公司股票被叠加实施退市风险警示的公告 后，*ST长药（300391）的股价在12月30日盘中一度跌停，当天收盘价报0.95元/股，下跌19.49%。 30日晚间，*ST长药发布公告，公司股票收盘价首次低于1元，可能因连续二十个交易日股票收盘价低于1元而被终止上市。同时，公司因涉嫌定期报告等 财务数据虚假记载被证监会立案调查，可能触及重大违法强制退市情形。此外，公司2024年度期末净资产为负，若2025年度期末净资产继续为负，将被实 施财务类强制退市。公司还面临诉讼、仲裁案件风险，大额有息负债逾期风险，账户冻结风险以及大额欠税风险。 对于股价跌破1元、法院裁定不予受理重整申请的影响，以及后续措施等，上证报记者以投资者身份致电*ST长药投资者专线，公司相关人士回应："不出 意外是要退市，暂无应对措施。" 在涉嫌触及重大违法强制退市情形前，*ST长药已存在财务类强制退市风险。 同时，据公司2022年、2023年、2024年年度报告，公司2022年、2023年、2024年度经审计的扣除非经常性损益后的净利润分别为-763 ...

金城医药公告，全资子公司北京金城泰尔制药有限公司收到北京市药品监督管理局核准签发的《药品 GMP符合性检查告知书》，其申报的米拉贝隆原料药已通过《药品生产质量管理规范（2010年修 订）》符合性检查。检查时间为2023年12月11日至15日，检查范围为米拉贝隆原料药（二车间米拉贝隆 生产线）。检查结论显示，该企业此次检查范围符合相关规范和附录要求。 ...

Core Viewpoint - The announcement highlights a significant contract signed by the company's wholly-owned subsidiary, Ausino, which is expected to contribute positively to the company's revenue and market position in the pharmaceutical supply chain [1][2]. Group 1: Contract Details - The contract signed on May 22, 2023, involves a total amount of approximately $102 million (including tax), with an actual performance amount of about $20 million (approximately RMB 143.53 million) for the year 2025, representing 8.83% of the company's audited revenue for 2024 and 29.05% of customized products and services revenue [1]. - The actual performance amount for 2025 exceeds the procurement guidance of $12.15 million by 65.43%, showcasing the company's technical strength and market competitiveness [1]. Group 2: Financial Impact - The successful execution of this contract is expected to have a positive impact on the company's operating performance for 2025, enhancing its sustainability and brand influence while expanding its overseas market [2]. - In the first three quarters of 2025, the company achieved revenue of RMB 1.527 billion, a year-on-year increase of 21.95%, and a net profit attributable to the parent company of RMB 445 million, up 26.92% year-on-year [2]. Group 3: International Strategy - The company has positioned internationalization as a core strategy, leveraging its technological advantages and production capacity to accelerate global market penetration [2]. - The company has established a sales network covering Europe, Latin America, India, and Africa, with peptide raw materials exported to 22 countries, including the United States, Europe, and Canada [2]. - The excess performance of the significant contract further validates the company's capability in expanding its overseas business [2].

Group 1 - The company, Shengda Bio, has a range of vitamin products including biotin and folic acid [2] - For raw material supply, the company primarily procures folic acid production materials through purchasing methods [2] - The company adopts a centralized procurement model for bulk raw materials to ensure high quality and stability of supply [2]

Core Viewpoint - The company acknowledges that drug research and development is significantly influenced by industry policies and market changes, highlighting the inherent risks associated with long cycles, high investments, and uncertainty in outcomes [2] Group 1: Drug Research and Development - The company is adjusting its drug research and development projects based on its own circumstances and external environmental factors [2] - Drug research projects that enter the registration process will have their progress disclosed through regular reports and temporary announcements [2]